%0 Journal Article
%T Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond
%A Wong, Nathan D.
%A Rosenblit, Paul D.
%A Greenfield, Rosenblit
%J Cardiovascular Diagnosis and Therapy
%D 2017
%B 2017
%9 
%! Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond
%K 
%X In 2003, select families with familial hypercholesterolemia were first identified to have gain-of-function mutations for proprotein convertase subtilisin kexin type 9 (PCSK9) followed, in 2006, by the identification of those with lifelong low levels of LDL-C and lowered atherosclerotic cardiovascular disease (ASCVD) risk who had loss-of-function PCSK9 mutations. These discoveries led to the rapid development of PSCK9-targeted monoclonal antibody (PCSK9 mAb) therapies and, in 2015, 2 ‘fully-humanized’ PCSK9 mAbs (alirocumab and evolocumab) were marketed in the United States, Europe, and other countries. In a wide range of high risk patients, with and without ASCVD, these PCSK9 mAbs, as once or twice monthly subcutaneous injections, potently reduce LDL-C 50–65% beyond levels achieved by maximally tolerated statin therapy; approximately one-third of patients achieve LDL-C levels 
%U https://cdt.amegroups.org/article/view/14520
%P S11-S20
%@ 2223-3660